<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Genetics</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Genetics</journal-title><trans-title-group xml:lang="ru"><trans-title>Генетика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0016-6758</issn><issn publication-format="electronic">3034-5103</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">666889</article-id><article-id pub-id-type="doi">10.31857/S0016675823020042</article-id><article-id pub-id-type="edn">KXHQJD</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>ГЕНЕТИКА ЧЕЛОВЕКА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Polygenic Analysis of Cytokine and Inflammatory Genes Polymorphisms in Chronic Obstructive Pulmonary Disease</article-title><trans-title-group xml:lang="ru"><trans-title>Полигенный анализ полиморфных локусов генов цитокинов и иммунного ответа при хронической обструктивной болезни легких</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Korytina</surname><given-names>G. F.</given-names></name><name xml:lang="ru"><surname>Корытина</surname><given-names>Г. Ф.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aznabaeva</surname><given-names>Y. G.</given-names></name><name xml:lang="ru"><surname>Азнабаева</surname><given-names>Ю. Г.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kochetova</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Кочетова</surname><given-names>О. В.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nasibullin</surname><given-names>T. R.</given-names></name><name xml:lang="ru"><surname>Насибуллин</surname><given-names>Т. Р.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Akhmadishina</surname><given-names>L. Z.</given-names></name><name xml:lang="ru"><surname>Ахмадишина</surname><given-names>Л. З.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khusnutdinova</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Хуснутдинова</surname><given-names>Н. Н.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zagidullin</surname><given-names>N. Sh.</given-names></name><name xml:lang="ru"><surname>Загидуллин</surname><given-names>Н. Ш.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Victorova</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Викторова</surname><given-names>Т. В.</given-names></name></name-alternatives><email>guly_kory@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Biochemistry and Genetics—Subdivision of the Ufa Federal Research Centre 
of the Russian Academy of Sciences (IBG UFRC RAS)</institution></aff><aff><institution xml:lang="ru">Институт биохимии и генетики – обособленное структурное подразделение Уфимского федерального исследовательского центра Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Bashkortostan State Medical University</institution></aff><aff><institution xml:lang="ru">Башкирский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-02-01" publication-format="electronic"><day>01</day><month>02</month><year>2023</year></pub-date><volume>59</volume><issue>2</issue><fpage>196</fpage><lpage>208</lpage><history><date date-type="received" iso-8601-date="2025-02-26"><day>26</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Г.Ф. Корытина, Ю.Г. Азнабаева, О.В. Кочетова, Т.Р. Насибуллин, Л.З. Ахмадишина, Н.Н. Хуснутдинова, Н.Ш. Загидуллин, Т.В. Викторова</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Г.Ф. Корытина, Ю.Г. Азнабаева, О.В. Кочетова, Т.Р. Насибуллин, Л.З. Ахмадишина, Н.Н. Хуснутдинова, Н.Ш. Загидуллин, Т.В. Викторова</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Г.Ф. Корытина, Ю.Г. Азнабаева, О.В. Кочетова, Т.Р. Насибуллин, Л.З. Ахмадишина, Н.Н. Хуснутдинова, Н.Ш. Загидуллин, Т.В. Викторова</copyright-holder><copyright-holder xml:lang="ru">Г.Ф. Корытина, Ю.Г. Азнабаева, О.В. Кочетова, Т.Р. Насибуллин, Л.З. Ахмадишина, Н.Н. Хуснутдинова, Н.Ш. Загидуллин, Т.В. Викторова</copyright-holder></permissions><self-uri xlink:href="https://transsyst.ru/0016-6758/article/view/666889">https://transsyst.ru/0016-6758/article/view/666889</self-uri><abstract xml:lang="en"><p id="idm45181323793040">Chronic obstructive pulmonary disease (COPD) is a complex lung disease characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. COPD pathogenesis was linked to oxidative stress and systemic inflammation. We aimed to assess the association of cytokines and inflammatory genes polymorphisms and their combinations with COPD. SNPs of inflammatory genes <italic>FASLG</italic> (rs763110), <italic>IL19</italic> (rs2243193), <italic>IL20</italic> (rs2981573), <italic>IL24</italic> (rs291107), <italic>PPBP</italic> (rs352010), <italic>IL4</italic> (rs2243250), <italic>IL4</italic> (rs2070874), <italic>С5</italic> (rs17611), <italic>FAS</italic> (rs1800682), <italic>IL4RA</italic> (rs1805010), <italic>TGFb1</italic> (rs1800469) was genotyped by the real-time polymerase chain reaction (PCR) among 601 COPD patients and 617 controls. Significant associations with COPD in the study group under additive genetic model were identified for <italic>IL19</italic> (rs2243193) (<italic>P</italic> = 0.00001, OR = 0.73), <italic>IL4</italic> (rs2243250) (<italic>P</italic> = 0.024, OR = 1.27), <italic>IL4</italic> (rs2070874) (<italic>P</italic> = 0.00001, OR = 0.62), and for <italic>PPBP</italic> (rs352010) under the recessive model (<italic>P</italic> = 0.00001, OR = 2.34). Using the APSampler algorithm, we obtained gene-gene combinations that remained significantly associated with COPD; <italic>A</italic> allele of <italic>IL19</italic> (rs2243193) and <italic>C</italic> allele of <italic>PPBP</italic> (rs352010) were the core element of the majority of protective patterns associated with COPD. The highest risk of COPD was conferred by combination of alleles: <italic>G</italic> of <italic>IL12A</italic> (rs2243115) with <italic>A</italic> of <italic>IL13</italic> (rs20541) and <italic>C</italic> of <italic>IL4</italic> (rs2070874) (OR = 2.72). The receiver operating characteristic (ROC) analysis resulted in an area under the curve (AUC) of 0.895 (95%CI 0.874–0.916) for model including SNPs: <italic>A</italic> allele of <italic>IL19</italic> (rs2243193) and <italic>AA</italic> genotype of <italic>IL20</italic> (rs2981573) combination, <italic>IL19</italic> (rs2243193), <italic>IL12A</italic> (rs2243115), <italic>PPBP</italic> (rs352010), <italic>IL4</italic> (rs2070874) together with age and smoking pack years, indicating a high ability of the model to correctly classify individuals with and without COPD.</p></abstract><trans-abstract xml:lang="ru"><p id="idm45181323784592">Хроническая обструктивная болезнь легких (ХОБЛ) является одним из наиболее распространенных хронических заболеваний органов дыхания с высоким уровнем заболеваемости и смертности. Патогенез ХОБЛ тесно связан с окислительным стрессом и системным воспалением. Цель настоящего исследования – выявление ассоциации полиморфных вариантов генов цитокинов и иммунного ответа с ХОБЛ. В работе были использованы образцы ДНК больных (<italic>N</italic> = 601) и здоровых (<italic>N</italic> = 617) индивидов. Полиморфные варианты генов <italic>FASLG</italic> (rs763110), <italic>IL19</italic> (rs2243193), <italic>IL20</italic> (rs2981573), <italic>IL24</italic> (rs291107), <italic>PPBP</italic> (rs352010), <italic>IL4</italic> (rs2243250, rs2070874), <italic>С5</italic> (rs17611), <italic>FAS</italic> (rs1800682), <italic>IL4RA</italic> (rs1805010), <italic>TGFb1</italic> (rs1800469) были проанализированы методом полимеразной цепной реакции в реальном времени. Показана ассоциация генов <italic>IL19</italic> (rs2243193) (<italic>P</italic> = 0.00001, OR = 0.73), <italic>IL4</italic> (rs2243250) (<italic>P</italic> = 0.024, OR = 1.27), <italic>IL4</italic> (rs2070874) (<italic>P</italic> = 0.00001, OR = 0.62) в лог-аддитивной модели, <italic>PPBP</italic> (rs352010) (<italic>P</italic> = 0.00001, OR = 2.34) в рецессивной модели с ХОБЛ. Для проведения полигенного анализа включали полиморфные локусы ранее изученных генов цитокинов (<italic>IL12RB2</italic>, <italic>IL12B</italic>, <italic>IL12A</italic>, <italic>IL13</italic>)<italic>.</italic> С помощью алгоритма APSampler получены информативные паттерны, ассоциированные с ХОБЛ; большинство наиболее значимых протективных комбинаций включали аллель <italic>A</italic> гена <italic>IL19</italic> (rs2243193) и аллель <italic>C</italic> или генотип <italic>TC</italic> гена <italic>PPBP</italic> (rs352010), а также генотип <italic>AA</italic> гена <italic>IL20</italic> (rs2981573)<italic>.</italic> Наибольший риск развития ХОБЛ определялся сочетанием аллелей трех функционально взаимосвязанных цитокинов: <italic>G</italic> гена <italic>IL12A</italic> (rs2243115), <italic>A</italic> гена <italic>IL13</italic> (rs20541) и <italic>C</italic> гена <italic>IL4</italic> (rs2070874) (OR = 2.72). По результатам множественного регрессионного и ROC-анализа получена прогностическая модель риска формирования ХОБЛ, включающая такие признаки как возраст и индекс курения, а также генетические маркеры: комбинация аллеля <italic>A IL19</italic> (rs2243193) и генотипа <italic>AA IL20</italic> (rs2981573), <italic>IL19</italic> (rs2243193), <italic>IL12A</italic> (rs2243115), <italic>PPBP</italic> (rs352010) и <italic>IL4</italic> (rs2070874) (AUC = 0.895, чувствительность – 85.5%, специфичность – 77.5%).</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic obstructive pulmonary disease</kwd><kwd>cytokine</kwd><kwd>inflammation</kwd><kwd>IL19</kwd><kwd>PPBP</kwd><kwd>gene–gene interactions.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких</kwd><kwd>цитокины</kwd><kwd>воспаление</kwd><kwd>полигенный анализ</kwd><kwd>IL19</kwd><kwd>PPBP</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease // J. Allergy Clin. Immunol. 2016. V. 138. № 1. P. 16–27. https://doi.org/10.1016/j.jaci.2016.05.011</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Hurst J.R., Siddiqui M.K., Singh B. et al. A systematic literature review of the humanistic burden of COPD // Int. J. Chron. Obstruct. Pulmon. Dis. 2021. V. 16. P. 1303–1314. https://doi.org/10.2147/COPD.S296696</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Silverman E.K. Genetics of COPD // Annu. Rev. Physiol. 2020. V. 82. P. 413–431. https://doi.org/10.1146/annurev-physiol-021317-121224</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ahmadi A., Ghaedi H., Salimian J. et al. Association between chronic obstructive pulmonary disease and interleukins gene variants: A systematic review and meta-analysis // Cytokine. 2019. V. 117. P. 65–71. https://doi.org/10.1016/j.cyto.2019.02.003</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Korytina G.F., Aznabaeva Y.G., Akhmadishina L.Z. et al. The relationship between chemokine and chemokine receptor genes polymorphisms and chronic obstructive pulmonary disease susceptibility in Tatar population from Russia: A case control study // Biochem. Genet. 2022. V. 60. № 1. P. 54–79. https://doi.org/10.1007/s10528-021-10087-2</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Korytina G.F., Akhmadishina L.Z., Aznabaeva Y.G. et al. Associations of the NRF2/KEAP1 pathway and antioxidant defense gene polymorphisms with chronic obstructive pulmonary disease // Gene. 2019. V. 692. P. 102–112. https://doi.org/10.1016/j.gene.2018.12.061</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ward L.D., Kellis M. HaploReg v4: Systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease // Nucl. Ac. Res. 2016. V. 44. № D1. P. D877–D881. https://doi.org/10.1093/nar/gkv1340</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Purcell S., Neale B., Todd-Brown K. et al. PLINK: A toolset for whole-genome association and population-based linkage analysis // Am. J. Hum. Genet. 2007. V. 81. № 3. P. 559–575. https://doi.org/10.1086/519795</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Favorov A.V., Andreewski T.V., Sudomoina M.A. et al. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans // Genetics. 2005. V. 171. № 4. P. 2113–2121. https://doi.org/10.1534/genetics.105.048090</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Корытина Г.Ф., Зулкарнеев Ш.Р., Азнабаева Ю.Г. и др. Вклад полиморфизмов генов IL12A, IL12B, IL13 и IL12RB2 в развитии хронической обструктивной болезни легких в этнической группе татар // Якутский мед. журнал. 2021. Т. 75. № 3. С. 21–25. https://doi.org/10.25789/YMJ.2021.75.05</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ouyang W., Rutz S., Crellin N.K. et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease // Annu. Rev. Immunol. 2011. V. 29. P. 71–109. https://doi.org/10.1146/annurev-immunol-031210-101312</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Azuma Y.T., Fujita T., Izawa T. et al. IL-19 contributes to the development of nonalcoholic steatohepatitis by altering lipid metabolism // Cells. 2021. V. 10. № 12. P. 3513. https://doi.org/10.3390/cells10123513</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wang W., Wang X., Yang K. et al. Association of BCL2 polymorphisms and the IL19 single nucleotide polymorphism rs2243188 with systemic lupus erythematosus // J. Int. Med. Res. 2021. V. 49. № 5. https://doi.org/10.1177/03000605211019187</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Leonard D., Svenungsson E., Dahlqvist J. et al. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis // Ann. Rheum. Dis. 2018. V. 77. № 7. P. 1063–1069. https://doi.org/10.1136/annrheumdis-2017-212614</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rong B., Liu Y., Li M. et al. Correlation of serum levels of HIF-1α and IL-19 with the disease progression of COPD: A retrospective study // Int. J. Chron. Obstruct. Pulmon. Dis. 2018. V. 13. P. 3791–3803. https://doi.org/10.2147/COPD.S177034</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Brown A.J., Joseph P.R., Sawant K.V. et al. Chemokine CXCL7 heterodimers: structural insights, CXCR2 receptor function, and glycosaminoglycan interactions // Int. J. Mol. Sci. 2017. V. 18. № 4. P. 748. https://doi.org/10.3390/ijms18040748</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bdeir K., Gollomp K., Stasiak M. et al. Platelet-specific chemokines contribute to the pathogenesis of acute lung injury // Am. J. Respir. Cell Mol. Biol. 2017. V. 56. № 2. P. 261–270. https://doi.org/10.1165/rcmb.2015-0245OC</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kousha A., Mahdavi Gorabi A., Forouzesh M. et al. Interleukin 4 gene polymorphism (–589C/T) and the risk of asthma: A meta-analysis and met-regression based on 55 studies // BMC Immunol. 2020. V. 21. № 1. P. 55. https://doi.org/10.1186/s12865-020-00384-7</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Choudhury P., Biswas S., Singh G. et al. Immunological profiling and development of a sensing device for detection of IL-13 in COPD and asthma // Bioelectrochemistry. 2022. V. 143. P. 107971. https://doi.org/10.1016/j.bioelechem.2021.107971</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dosreis G.A., Borges V.M., Zin W.A. The central role of Fas-ligand cell signaling in inflammatory lung diseases // J. Cell Mol. Med. 2004. V. 8. № 3. P. 285–293. https://doi.org/10.1111/j.1582-4934.2004.tb00318.x</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Caramori G., Adcock I.M., Di Stefano A. et al. Cytokine inhibition in the treatment of COPD // Int. J. Chron. Obstruct. Pulmon. Dis. 2014. V. 9. P. 397–412. https://doi.org/10.2147/COPD.S42544</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Tam A., Leclair P., Li L. et al. FAM13A as potential therapeutic target in modulating TGF-β-induced airway tissue remodeling in COPD // Am. J. Physiol. Lung Cell Mol. Physiol. 2021. V. 321. № 2. P. L377–L391. https://doi.org/10.1152/ajplung.00477.2020</mixed-citation></ref></ref-list></back></article>
